Beckley Canopy Therapeutics
Clinically validated cannabis-based medicines intellectual property research.
| Date | Investors | Amount | Round |
|---|---|---|---|
£7.4m | Late VC | ||
| Total Funding | 000k | ||
Related Content
Beckley Canopy Therapeutics was a biopharmaceutical company focused on the research and development of clinically validated cannabis-based medicines and the protection of its associated intellectual property. It was established as a joint venture in January 2018, headquartered in Oxford, UK. The company was a partnership between the drug research pioneer Lady Amanda Feilding's Beckley Foundation and Canopy Growth Corporation, a major Canadian cannabis company. Cosmo Feilding Mellen, who previously co-founded Beckley Research & Innovations, served as the co-managing director alongside Marc Wayne of Canopy Health Innovations.
The company's business model was centered on conducting clinical research to build an intellectual property portfolio and develop innovative cannabis-based pharmaceutical and natural health products. Its initial research areas included cancer pain, opioid sparing, and smoking cessation. The venture combined the Beckley Foundation's extensive scientific research network with Canopy Growth's commercial and product development capabilities. The goal was to provide evidence-based cannabis formulations for patients and secure regulatory approval for their use. In August 2018, the company formed a joint venture with Spectrum Biomedical UK to serve as its commercial arm in the United Kingdom.
In October 2019, Canopy Growth Corporation acquired all outstanding shares of Beckley Canopy Therapeutics. Following the acquisition, the company and its teams were fully integrated into Canopy Growth's global medical division, Spectrum Therapeutics, to consolidate research and commercial efforts in Europe. This strategic move was intended to strengthen Canopy's clinical research programs and expand patient access to cannabinoid-based medicines across the continent.
Keywords: cannabis research, cannabinoid-based medicines, intellectual property protection, biopharmaceutical, clinical trials, medical cannabis, drug development, opioid sparing, cancer pain research, pharmaceutical research, Spectrum Therapeutics, Canopy Growth, Beckley Foundation, Lady Amanda Feilding, Cosmo Feilding Mellen, cannabis formulations